News and Events
April 28, 2025
No items found.

Episode 10, “Revisiting Seamless 2/3 Trial for GLP-1 Agonist"

Play video
No items found.
In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better known as Trulicity.

In the latest episode of "In the Interim..." we dissect the intricacies and breakthroughs of the groundbreaking AWARD-5 trial for Eli Lilly’s dulaglutide, now known as Trulicity. Discover how we overcame design challenges, integrated innovative statistical methods, and navigated regulatory hurdles.

𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

—Seamless Phase 2/3 trial integration for GLP-1 Agonist

—Intricacies of Bayesian algorithms and adaptive randomization

—Collaborative efforts between Berry Consultants, Eli Lilly, and regulatory bodies

This episode is a must-listen for anyone involved in clinical trial design or interested in cutting-edge statistical approaches. Don't miss it! https://www.berryconsultants.com/resource/10-revisiting-seamless-2-3-trial-for-glp-1-agonist

Download PDF
View